Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:LQDA

Liquidia Q2 2026 Earnings Report

Liquidia logo
$79.97 +2.89 (+3.75%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Liquidia EPS Results

Actual EPS
N/A
Consensus EPS
$0.76
Beat/Miss
N/A
One Year Ago EPS
N/A

Liquidia Revenue Results

Actual Revenue
N/A
Expected Revenue
$168.48 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Liquidia Announcement Details

Quarter
Q2 2026
Date
8/11/2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Liquidia Earnings Headlines

Beat the market the Zacks way: Liquidia, BILL, Colgate-Palmolive in focus
July 20 at 1:35 PM  |  msn.comhttps://www.msn.com/en-us/money/markets/beat-the-market-the-zacks-way-liquidia-bill-colgate-palmolive-in-focus/ar-AA28i0UD
Structure Therapeutics (NASDAQ:GPCR) versus Liquidia (NASDAQ:LQDA) Head to Head Comparison
July 20 at 3:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30910124
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
July 21 at 1:00 AM  |  Porter & Company (Ad)
Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $709,808.26 in Stock
July 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30904480
Liquidia (NASDAQ:LQDA) CAO Sells $643,733.02 in Stock
July 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30904481
Liquidia (NASDAQ:LQDA) Insider Sells $682,133.89 in Stock
July 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30904469
See More Liquidia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia and other key companies, straight to your email.

About Liquidia

Liquidia (NASDAQ:LQDA) Technologies, Inc. is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH). LIQ861 aims to offer a more convenient and potentially more consistent dosing approach compared with current liquid-based nebulized therapies. Besides PAH, Liquidia is exploring additional indications and dosage forms to expand the use of its PRINT platform, including collaborations focused on vaccine adjuvants and other respiratory applications.

Liquidia Technologies was founded to translate advanced particle-engineering science into therapeutic benefit and has assembled a team with experience in respiratory drug development, regulatory affairs and clinical operations. The company conducts clinical research primarily in the United States, and it plans to pursue regulatory filings in major markets following the completion of pivotal studies. Under the leadership of President and CEO Chris Critelli, Liquidia continues to advance its pipeline toward potential commercialization.

View Liquidia Profile
Earnings Tools